問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Linkou Chang Gung Medical Foundation (在職)

Division of General Internal Medicine

Division of Rheumatology

更新時間：2023-09-19

謝臻怡Hsieh, Chen-I
  • Principal Investigator
  • Clinical Trial Experience (year) 7 years 9 個月

  • jennifershie@cgmh.org.tw

Recruiting Trial

13Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

謝臻怡

Linkou Chang Gung Medical Foundation

Division of Rheumatology

List

9Cases

2021-06-01 - 2026-06-30

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Not yet recruiting3Sites

Recruiting7Sites

2021-07-09 - 2026-05-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-07-01 - 2027-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2023-07-31 - 2026-04-30

Phase II/III

Completed
A Multicenter, Randomized, Double-blind, Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout

  • Condition/Disease

    Gout

  • Test Drug

    ABP-671

Participate Sites
4Sites

Recruiting3Sites

Study ended1Sites

2020-12-01 - 2025-12-31

Phase IV

Active
Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis: a 12 Month, Single-arm, Observational Study in Taiwan Population

  • Condition/Disease

    Lupus Nephritis

  • Test Drug

    Myfortic 180 mg、360 mg Gastro-Resistant Tablets

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2021-08-01 - 2025-01-24

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting3Sites

Recruiting2Sites

Terminated1Sites

2021-07-09 - 2026-05-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2023-07-01 - 2027-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Not yet recruiting2Sites

2023-07-31 - 2026-04-30

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB